IGF-1 LR3 1000mcg – Apoxar IGF-1 LR3 (Insulin-Like Growth Factor-1 Long R3) – Compound Profile is a modified version of the naturally occurring Insulin-Like Growth Factor-1 (IGF-1). It has been engineered for enhanced stability, potency, and bioavailability, making it a popular choice among athletes and bodybuilders for its muscle growth and recovery benefits. Apoxar IGF-1 LR3 1000mcg refers to a high-quality, research-grade peptide commonly sold in lyophilized (powder) form for reconstitution. Key Features of IGF-1 LR3 Extended Half-Life: Unlike native IGF-1 (half-life: ~20–30 minutes), IGF-1 LR3 has a significantly extended half-life of ~20–30 hours, enabling once-daily administration. Enhanced Binding Properties: Modified to avoid binding to IGF-binding proteins (IGFBPs), allowing more active IGF-1 to circulate in the bloodstream and exert its effects. Anabolic Potency: Promotes muscle hypertrophy, cell growth, and repair. Potentiates the effects of growth hormone (GH). Mechanism of Action IGF-1 LR3 mimics the actions of natural IGF-1 by binding to IGF-1 receptors in muscle, bone, and connective tissues. This activation leads to: Protein Synthesis: Promotes muscle growth and recovery. Cellular Proliferation: Stimulates cell division and repair in various tissues. Nutrient Partitioning: Directs glucose and amino acids into muscle cells for growth. Benefits of IGF-1 LR3 Muscle Growth: Enhances lean muscle tissue growth by increasing protein synthesis and satellite cell activation. Fat Loss: Improves insulin sensitivity and promotes fat oxidation, making it ideal for body recomposition. Improved Recovery: Speeds up recovery from intense workouts by repairing muscle fibers and reducing inflammation. Anti-Aging Effects: Supports skin elasticity, bone density, and overall tissue health. Joint and Tendon Repair: Promotes healing of connective tissues, reducing injury risk. Dosage and Administration Standard Dosage: 20–50 mcg/day, depending on individual goals and tolerance. Some advanced users may go up to 100 mcg/day, but this is less common. Injection Timing: Administer subcutaneously (SC) or intramuscularly (IM) in the morning or post-workout for optimal results. Cycle Duration: Typically used for 4–6 weeks, followed by an equal time off to avoid desensitization. Reconstitution and Storage Reconstitution: Mix the 1000mcg (1mg) vial of IGF-1 LR3 with bacteriostatic water or sterile water. For example, if reconstituting with 1 mL of bacteriostatic water, the concentration will be 1000 mcg/mL (1 mcg/μL). Storage: Lyophilized Powder: Store in a cool, dry place (e.g., refrigerator) before reconstitution. After Reconstitution: Store in the refrigerator (2–8°C) and use within 20–30 days. Potential Side Effects While IGF-1 LR3 is generally well-tolerated, some users may experience side effects, including: Common: Hypoglycemia (low blood sugar): IGF-1 enhances insulin sensitivity. Localized swelling or irritation at the injection site. Less Common: Headaches. Joint pain (related to rapid growth or repair). Mild water retention. Rare: Excessive growth of tissues (e.g., organs or cartilage) if abused. Insulin resistance with long-term or high-dose use. Stacking Protocols IGF-1 LR3 is often used alongside other compounds for enhanced results: With Growth Hormone (GH): Amplifies the anabolic effects of GH by increasing IGF-1 levels systemically. With Anabolic Steroids: Synergizes with steroids like Testosterone or Nandrolone for rapid muscle growth. With Peptides: Combined with GHRP-6 or CJC-1295 to boost growth hormone release and enhance recovery. Safety and Monitoring Monitoring: Regular blood glucose checks to avoid hypoglycemia. Periodic blood tests to assess IGF-1 levels and ensure safety. Avoiding Desensitization: Do not exceed recommended cycles or doses to prevent receptor downregulation. Legal and Research Considerations Research Status: IGF-1 LR3 is classified as a research peptide and is not FDA-approved for therapeutic use. Legal Use: Availability may vary depending on regional regulations; ensure compliance with local laws.
